Photo from archive.org
We are now transitioning into the era of personalised tailored therapy with the application of risk stratification schemes based on easily measured clinical markers beautifully illustrated in determining the risk:benefit… Click to show full abstract
We are now transitioning into the era of personalised tailored therapy with the application of risk stratification schemes based on easily measured clinical markers beautifully illustrated in determining the risk:benefit of anticoagulation in AF patients. The evolution of the CHADS score to CHA2DS2-VASc has refined therapeutic risk assessment coupled with the HASBLED score to assess bleeding risk. However, despite their apparent simplicity to ensure their utility, these scoring systems paper over a number of cracks in our knowledge base as reviewed in the paper by Professor Lip's group.
Journal Title: International journal of cardiology
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!